Northland Capital Markets Downgrades Cardlytics to Market Perform, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Northland Capital Markets has downgraded Cardlytics (NASDAQ:CDLX) from Outperform to Market Perform and lowered its price target from $7 to $5.
August 16, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Northland Capital Markets has downgraded Cardlytics from Outperform to Market Perform and reduced the price target from $7 to $5.
The downgrade from Outperform to Market Perform and the reduction in the price target from $7 to $5 by Northland Capital Markets is likely to negatively impact Cardlytics' stock price in the short term. Such downgrades typically signal reduced confidence in the company's near-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100